Inhibition of IgE-mediated Secretion from Human Basophils with a Highly Selective Bruton’s Tyrosine Kinase, Btk, Inhibitor

Por MacGlashan, Donald, Honigberg, Lee, Smith, Ashley, Buggy, Joseph, Schroeder, John T.
Publicado em 2011

HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination

Por Adimoolam, Shanthi, Sirisawad, Mint, Chen, Jun, Thiemann, Patti, Ford, James M., Buggy, Joseph J.
Publicado em 2007

Issues in the management of prisoners infected with HIV-1: the King's College Hospital HIV prison service retrospective cohort study

Por Edwards, Simon, Tenant-Flowers, Melinda, Buggy, Joseph, Horne, Peter, Hulme, Nick, Easterbrook, Philippa, Taylor, Chris
Publicado em 2001

The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells

Por Chang, Betty Y, Huang, Min Mei, Francesco, Michelle, Chen, Jun, Sokolove, Jeremy, Magadala, Padmaja, Robinson, William H, Buggy, Joseph J
Publicado em 2011

The Histone Deacetylase Inhibitor PCI-24781 Induces Caspase and ROS-Dependent Apoptosis Through NF-kB and is Synergistic with Bortezomib in Lymphoma Cells

Por Bhalla, Savita, Balasubramanian, Sriram, David, Kevin, Sirisawad, Mint, Buggy, Joseph, Mauro, Lauren, Prachand, Sheila, Miller, Richard, Gordon, Leo I., Evens, Andrew M.
Publicado em 2009

Modeling Pharmacological Inhibition of Mast Cell Degranulation as a Therapy for Insulinoma

Por Soucek, Laura, Buggy, Joseph J, Kortlever, Roderik, Adimoolam, Shanthi, Monclús, Helena Allende, Allende, Maria Teresa Salcedo, Swigart, Lamorna Brown, Evan, Gerard I
Publicado em 2011

Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus

Por Hutcheson, Jack, Vanarsa, Kamala, Bashmakov, Anna, Grewal, Simer, Sajitharan, Deena, Chang, Betty Y, Buggy, Joseph J, Zhou, Xin J, Du, Yong, Satterthwaite, Anne B, Mohan, Chandra
Publicado em 2012

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo

Por Ponader, Sabine, Chen, Shih-Shih, Buggy, Joseph J., Balakrishnan, Kumudha, Gandhi, Varsha, Wierda, William G., Keating, Michael J., O'Brien, Susan, Chiorazzi, Nicholas, Burger, Jan A.
Publicado no Blood (2012)

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

Por Honigberg, Lee A., Smith, Ashley M., Sirisawad, Mint, Verner, Erik, Loury, David, Chang, Betty, Li, Shyr, Pan, Zhengying, Thamm, Douglas H., Miller, Richard A., Buggy, Joseph J.
Publicado em 2010

Ibrutinib antagonizes rituximab-dependent NK cell–mediated cytotoxicity

Por Kohrt, Holbrook E., Sagiv-Barfi, Idit, Rafiq, Sarwish, Herman, Sarah E. M., Butchar, Jonathon P., Cheney, Carolyn, Zhang, Xiaoli, Buggy, Joseph J., Muthusamy, Natarajan, Levy, Ronald, Johnson, Amy J., Byrd, John C.
Publicado em 2014

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765

Por Herman, Sarah E. M., Gordon, Amber L., Hertlein, Erin, Ramanunni, Asha, Zhang, Xiaoli, Jaglowski, Samantha, Flynn, Joseph, Jones, Jeffrey, Blum, Kristie A., Buggy, Joseph J., Hamdy, Ahmed, Johnson, Amy J., Byrd, John C.
Publicado em 2011

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

Por Advani, Ranjana H., Buggy, Joseph J., Sharman, Jeff P., Smith, Sonali M., Boyd, Thomas E., Grant, Barbara, Kolibaba, Kathryn S., Furman, Richard R., Rodriguez, Sara, Chang, Betty Y., Sukbuntherng, Juthamas, Izumi, Raquel, Hamdy, Ahmed, Hedrick, Eric, Fowler, Nathan H.
Publicado no J Clin Oncol (2013)

Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

Por Chang, Betty Y., Francesco, Michelle, De Rooij, Martin F. M., Magadala, Padmaja, Steggerda, Susanne M., Huang, Min Mei, Kuil, Annemieke, Herman, Sarah E. M., Chang, Stella, Pals, Steven T., Wilson, Wyndham, Wiestner, Adrian, Spaargaren, Marcel, Buggy, Joseph J., Elias, Laurence
Publicado em 2013

Modeling Tumor-Host Interactions of Chronic Lymphocytic Leukemia in Xenografted Mice to Study Tumor Biology and Evaluate Targeted Therapy

Por Herman, Sarah E. M., Sun, Xiameng, McAuley, Erin M., Hsieh, Matthew M., Pittaluga, Stefania, Raffeld, Mark, Liu, Delong, Keyvanfar, Keyvan, Chapman, Colby M., Chen, Jichun, Buggy, Joseph J., Aue, Georg, Tisdale, John F., Pérez-Galán, Patricia, Wiestner, Adrian
Publicado em 2013

Bruton’s tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)

Por Woyach, Jennifer A., Bojnik, Engin, Ruppert, Amy S., Stefanovski, Matthew R., Goettl, Virginia M., Smucker, Kelly A., Smith, Lisa L., Dubovsky, Jason A., Towns, William H., MacMurray, Jessica, Harrington, Bonnie K., Davis, Melanie E., Gobessi, Stefania, Laurenti, Luca, Chang, Betty Y., Buggy, Joseph J., Efremov, Dimitar G., Byrd, John C., Johnson, Amy J.
Publicado em 2014

Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma

Por Yang, Yibin, Shaffer, Arthur L., Emre, N.C. Tolga, Ceribelli, Michele, Zhang, Meili, Wright, George, Xiao, Wenming, Powell, John, Platig, John, Kohlhammer, Holger, Young, Ryan M., Zhao, Hong, Yang, Yandan, Xu, Weihong, Buggy, Joseph J., Balasubramanian, Sriram, Mathews, Lesley A., Shinn, Paul, Guha, Rajarshi, Ferrer, Marc, Thomas, Craig, Waldmann, Thomas A., Staudt, Louis M.
Publicado em 2012

Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma

Por Tai, Yu-Tzu, Chang, Betty Y., Kong, Sun-Young, Fulciniti, Mariateresa, Yang, Guang, Calle, Yolanda, Hu, Yiguo, Lin, Jianhong, Zhao, Jian-Jun, Cagnetta, Antonia, Cea, Michele, Sellitto, Michael A., Zhong, Mike Y., Wang, Qiuju, Acharya, Chirag, Carrasco, Daniel R., Buggy, Joseph J., Elias, Laurence, Treon, Steven P., Matsui, William, Richardson, Paul, Munshi, Nikhil C., Anderson, Kenneth C.
Publicado em 2012

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

Por Byrd, John C., Furman, Richard R., Coutre, Steven E., Flinn, Ian W., Burger, Jan A., Blum, Kristie A., Grant, Barbara, Sharman, Jeff P., Coleman, Morton, Wierda, William G., Jones, Jeffrey A., Zhao, Weiqiang, Heerema, Nyla A., Johnson, Amy J., Sukbuntherng, Juthamas, Chang, Betty Y., Clow, Fong, Hedrick, Eric, Buggy, Joseph J., James, Danelle F., O'Brien, Susan
Publicado em 2013

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

Por O’Brien, Susan, Furman, Richard R, Coutre, Steven E, Sharman, Jeff P, Burger, Jan A, Blum, Kristie A, Grant, Barbara, Richards, Donald A, Coleman, Morton, Wierda, William G, Jones, Jeffrey A, Zhao, Weiqiang, Heerema, Nyla A, Johnson, Amy J, Izumi, Raquel, Hamdy, Ahmed, Chang, Betty Y, Graef, Thorsten, Clow, Fong, Buggy, Joseph J, James, Danelle F, Byrd, John C
Publicado em 2013

Resistance Mechanisms for the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib

Por Woyach, Jennifer A., Furman, Richard R., Liu, Ta-Ming, Ozer, Hatice Gulcin, Zapatka, Marc, Ruppert, Amy S., Xue, Ling, Li, Daniel Hsieh-Hsin, Steggerda, Susanne M., Versele, Matthias, Dave, Sandeep S., Zhang, Jenny, Yilmaz, Ayse Selen, Jaglowski, Samantha M., Blum, Kristie A., Lozanski, Arletta, Lozanski, Gerard, James, Danelle F., Barrientos, Jacqueline C., Lichter, Peter, Stilgenbauer, Stephan, Buggy, Joseph J., Chang, Betty Y., Johnson, Amy J., Byrd, John C.
Publicado em 2014